HK1131619A1 - 激活抑制劑 - Google Patents

激活抑制劑

Info

Publication number
HK1131619A1
HK1131619A1 HK09111385.1A HK09111385A HK1131619A1 HK 1131619 A1 HK1131619 A1 HK 1131619A1 HK 09111385 A HK09111385 A HK 09111385A HK 1131619 A1 HK1131619 A1 HK 1131619A1
Authority
HK
Hong Kong
Prior art keywords
stat3
activation inhibitor
inhibitor
activation
inhibitor stat3
Prior art date
Application number
HK09111385.1A
Other languages
English (en)
Inventor
和生 關口
鈴木　敬
豐 大渕
貢廣 奧野
直人 大井
大西　健司
晶章 本山
吉田　憲司
健志 兒玉
和久 杉山
聖司 赤松
邦彥 清野
康夫 柳原
隆司 渡邊
彥 林
英男 田中
卓美 住田
Original Assignee
大塚制藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大塚制藥株式會社 filed Critical 大塚制藥株式會社
Publication of HK1131619A1 publication Critical patent/HK1131619A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK09111385.1A 2006-10-02 2009-12-03 激活抑制劑 HK1131619A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006271172 2006-10-02
PCT/JP2007/069645 WO2008044667A1 (en) 2006-10-02 2007-10-02 Stat3/5 activation inhibitor

Publications (1)

Publication Number Publication Date
HK1131619A1 true HK1131619A1 (zh) 2010-01-29

Family

ID=38896700

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09111385.1A HK1131619A1 (zh) 2006-10-02 2009-12-03 激活抑制劑

Country Status (20)

Country Link
US (2) US8263599B2 (zh)
EP (2) EP2089373A1 (zh)
JP (1) JP5068821B2 (zh)
KR (1) KR101148805B1 (zh)
CN (1) CN101522657B (zh)
AR (1) AR063073A1 (zh)
AU (1) AU2007305511A1 (zh)
BR (1) BRPI0717218A2 (zh)
CA (1) CA2665000C (zh)
HK (1) HK1131619A1 (zh)
IL (1) IL197723A (zh)
MX (1) MX2009003256A (zh)
MY (1) MY150229A (zh)
NO (1) NO20090856L (zh)
NZ (1) NZ598061A (zh)
RU (1) RU2489148C2 (zh)
TW (1) TWI336699B (zh)
UA (1) UA95978C2 (zh)
WO (1) WO2008044667A1 (zh)
ZA (1) ZA200901874B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2416608C2 (ru) 2004-08-06 2011-04-20 Оцука Фармасьютикал Ко., Лтд. Ароматическое соединение
JP2009508835A (ja) 2005-09-16 2009-03-05 アロー セラピューティクス リミテッド ビフェニル誘導体及びｃ型肝炎の治療におけるその使用
PL1957073T3 (pl) * 2005-12-05 2014-09-30 Otsuka Pharma Co Ltd Substancja lecznicza
AU2009269410B2 (en) 2008-07-10 2013-12-05 General Incorporated Association Pharma Valley Project Supporting Organisation STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient
JP5688918B2 (ja) * 2009-04-28 2015-03-25 大塚製薬株式会社 医薬組成物
NZ600837A (en) * 2009-12-28 2014-01-31 Gen Inc Ass Pharma Valley Project Supporting Organization 1,3,4-oxadiazole-2-carboxamide compound
PT2528897E (pt) * 2010-01-29 2014-11-12 Otsuka Pharma Co Ltd Derivados de piridina dissubstituída como anticancerígenos
SI2624833T1 (sl) * 2010-10-04 2015-03-31 Otsuka Pharmaceutical Co., Ltd. Derivati 4-(metilaminofenoksi)piridin-3-il-benzamida za zdravljenje raka
CN102921007B (zh) * 2011-08-09 2014-12-10 中国科学院上海生命科学研究院 防治胰岛素抵抗和糖尿病的方法和试剂
TW201329025A (zh) 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
JP6066806B2 (ja) * 2012-04-03 2017-01-25 大塚製薬株式会社 医薬
CA2874057A1 (en) * 2012-05-25 2013-11-28 The Governing Council Of The University Of Toronto New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
CN103880707B (zh) * 2012-12-19 2016-04-13 上海交通大学医学院 Stat3小分子抑制剂及其应用
US10253027B2 (en) * 2013-07-08 2019-04-09 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
ES2842592T3 (es) * 2014-05-19 2021-07-14 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos
RU2707094C2 (ru) * 2014-05-30 2019-11-22 Зе Гавернинг Каунсл Оф Зе Юниверсити Оф Торонто Соединения сульфонамида и их применение в качестве ингибиторов stat5
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
US11311513B2 (en) 2017-04-26 2022-04-26 University Of Cincinnati Methods, agents, and compositions for the treatment of acute myeloid leukemia
TWI650120B (zh) * 2017-07-21 2019-02-11 寶騰生醫股份有限公司 一種醫藥組成物用於製備治療或預防個體感染病毒之藥物的用途
US10882821B1 (en) 2017-09-26 2021-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
WO2019230039A1 (ja) 2018-06-01 2019-12-05 日洋サービス株式会社 植物の栽培方法及び植物の栽培装置
CN111763217B (zh) * 2019-03-30 2022-06-28 上海凌达生物医药有限公司 一类噻吩并氮杂环类化合物、制备方法和用途
TW202106676A (zh) 2019-04-05 2021-02-16 美商凱麥拉醫療公司 Stat降解劑及其用途
WO2021024375A1 (ja) 2019-08-06 2021-02-11 正月 白川 植物の栽培方法及び植物の栽培装置
RU2742188C1 (ru) * 2020-07-22 2021-02-03 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. Способ лечения оптической нейропатии у больных с отечным экзофтальмом
CN116715657A (zh) * 2023-04-19 2023-09-08 河南省锐达医药科技有限公司 一种二芳基乙炔类化合物、其制备方法及应用
CN117362206B (zh) * 2023-12-08 2024-02-20 四川大学华西第二医院 一类芳基磺酰胺类化合物、合成方法及用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE629102A (zh) 1961-03-29
US3715375A (en) 1970-09-17 1973-02-06 Merck & Co Inc New diphenyl sulfones
NL7111711A (zh) 1970-09-17 1972-03-21
GB1494117A (en) 1974-11-02 1977-12-07 Bayer Ag Process for the preparation of acid amides
DE2707659A1 (de) 1977-02-23 1978-08-24 Bayer Ag Selbstvernetzbare polyurethane
DE2707660C2 (de) 1977-02-23 1985-12-19 Bayer Ag, 5090 Leverkusen Abspalter- und Diolrest enthaltende Diisocyanat-Addukte, ihre Herstellung und Verwendung
DE2812252A1 (de) 1978-03-21 1979-10-04 Bayer Ag 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
EP0500495A3 (en) 1991-02-21 1993-04-07 Ciba-Geigy Ag Thermosetting composition
DK0580550T3 (da) 1992-07-21 1998-02-02 Ciba Geigy Ag Oxamidsyrederivater som hypercholesterolæmiske midler
US5776951A (en) 1993-06-30 1998-07-07 Glaxo Wellcome Inc. Anti-atherosclerotic diaryl compounds
IL122341A0 (en) 1995-06-07 1998-04-05 Inst Materia Medica Retinoid derivatives and their use
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
EP1060171A2 (de) 1998-02-06 2000-12-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tryptase-inhibitoren
AU2924699A (en) 1998-02-06 1999-08-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
AR015733A1 (es) 1998-03-25 2001-05-16 Otsuka Pharma Co Ltd DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO.
TWI245035B (en) 1998-06-26 2005-12-11 Ono Pharmaceutical Co Amino acid derivatives and a pharmaceutical composition comprising the derivatives
EP1101755B1 (en) 1998-07-24 2004-10-06 Teijin Limited Anthranilic acid derivatives
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2871900A (en) 1999-02-04 2000-08-25 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
US6159694A (en) 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
CA2377771A1 (en) 1999-07-01 2001-01-11 Ajinomoto Co., Inc. Heterocyclic compounds and medical use thereof
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
JP2001089450A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ピリジン誘導体含有医薬製剤
AU3408901A (en) 2000-02-15 2001-08-27 Teijin Ltd Cancer remedy comprising anthranilic acid derivative as active ingredient
BR0111206A (pt) 2000-05-22 2003-04-15 Aventis Pharma Inc Derivados de arilmetilamina para uso como inibidores de triptase
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
EP1379127B1 (en) 2000-09-28 2013-04-17 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
AU2002223626A1 (en) 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
EP1211235A3 (en) 2000-11-30 2004-01-02 JFE Chemical Corporation Preparation process of 4,4'-Dicarboxydiphenyl ethers or derivatives thereof
JP2004269356A (ja) 2000-12-27 2004-09-30 Ajinomoto Co Inc 創傷部癒着防止剤
GB2374009A (en) 2001-02-12 2002-10-09 Novartis Ag Method of treating hair loss
UA74266C2 (uk) 2001-06-20 2005-11-15 Пфайзер Продактс Інк. Похідні сульфонових кислот, фармацевтична композиція та спосіб лікування запалень та інших розладів імунної системи
EP1419162A1 (en) 2001-08-24 2004-05-19 Pharmacia & Upjohn Company Substituted-aryl 7-aza 2.2.1]bicycloheptanes for the treatment of disease
IL160974A0 (en) 2001-10-22 2004-08-31 Pfizer Prod Inc Piperazine derivatives with ccr1 receptor antagonist activity
WO2003035602A1 (fr) 2001-10-25 2003-05-01 Sankyo Company, Limited Modulateurs lipidiques
BR0307714A (pt) 2002-02-15 2005-02-09 Upjohn Co Benzoilamidas substituìdas com azabiciclo e tioamidas para tratamento de distúrbios relacionados ao cns
FR2836917B1 (fr) * 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
JP2004035475A (ja) 2002-07-03 2004-02-05 Ajinomoto Co Inc ＴＧＦβ作用抑制剤
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
RU2396250C2 (ru) 2003-07-24 2010-08-10 Лео Фарма А/С Новые производные аминобензофенона
RU2416608C2 (ru) * 2004-08-06 2011-04-20 Оцука Фармасьютикал Ко., Лтд. Ароматическое соединение
PL1957073T3 (pl) 2005-12-05 2014-09-30 Otsuka Pharma Co Ltd Substancja lecznicza
TWI440638B (zh) 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物

Also Published As

Publication number Publication date
EP2089373A1 (en) 2009-08-19
ZA200901874B (en) 2010-07-28
CN101522657A (zh) 2009-09-02
CA2665000C (en) 2015-03-24
RU2009116653A (ru) 2010-11-10
MX2009003256A (es) 2009-04-08
IL197723A (en) 2015-02-26
AR063073A1 (es) 2008-12-23
JP5068821B2 (ja) 2012-11-07
BRPI0717218A2 (pt) 2013-09-24
JP2010505762A (ja) 2010-02-25
KR101148805B1 (ko) 2012-07-10
KR20090043008A (ko) 2009-05-04
MY150229A (en) 2013-12-31
AU2007305511A1 (en) 2008-04-17
CA2665000A1 (en) 2008-04-17
TWI336699B (en) 2011-02-01
RU2489148C2 (ru) 2013-08-10
US20120322807A1 (en) 2012-12-20
NZ598061A (en) 2013-05-31
US8263599B2 (en) 2012-09-11
IL197723A0 (en) 2009-12-24
UA95978C2 (ru) 2011-09-26
WO2008044667A1 (en) 2008-04-17
TW200823189A (en) 2008-06-01
NO20090856L (no) 2009-03-27
US20100210661A1 (en) 2010-08-19
CN101522657B (zh) 2014-10-15
EP2612858A1 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
ZA200901874B (en) Stat3/5 activation inhibitor
EP1963462A4 (en) CORROSION INHIBITOR
GB0516967D0 (en) Inhibitors
GB0606655D0 (en) Showerpod 1
GB0520876D0 (en) Corrosion inhibitor
GB0624628D0 (en) Duty 3
GB0506443D0 (en) Novel inhibitors
GB0603565D0 (en) Moveclick 11
GB0604493D0 (en) Corcost 4
GB0615357D0 (en) Corcost 2006
GB0615330D0 (en) Corcost 2006
GB0615059D0 (en) Corcost 506
GB0615056D0 (en) Corcost 106
GB0615051D0 (en) Corcost 1306
GB0615050D0 (en) Corcost 706
GB0612310D0 (en) Corcost 1506
GB0612239D0 (en) Corcost 106
GB0612198D0 (en) Corcost 406
GB0610406D0 (en) MoveClick 18
GB0604926D0 (en) MoveClick 15
GB0604639D0 (en) Corcost 13
GB0604638D0 (en) Corcost 11
GB0604637D0 (en) Corcost 10
GB0604636D0 (en) Corcost 9
GB0604633D0 (en) Corcost 12

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181002